Vaccines fail faster in people with obesity because their immune systems cannot maintain protective antibodies over time. The researcher has traced this problem to dysregulated IL-6 signalling, a molecular pathway that controls inflammation and antibody production. Now they want to test whether the same mechanism explains weaker vaccine responses in older people, and to study antibody maintenance directly in lymph nodes and in mouse models that mimic human immune variability. If the link holds, the team will design modified-mRNA vaccines that compensate for individual immune weaknesses—the same platform already used to tailor vaccines against viral variants or tumour mutations. This is fundamental science with a clear practical target: as the UK population grows older and heavier, standard one-size-fits-all vaccines will leave more people unprotected. A deeper understanding of why some immunotypes fail to sustain antibodies could eventually allow vaccines to be adjusted for age or weight, closing a widening gap in protection that current public health interventions do not address.
View original technical description
Vaccination is the most effective public health intervention, protecting us from infectious diseases and cancer. However, human variability in vaccine response leads to significant health inequalities. The individuals immunological status or 'immunotype'—impacted by genetic differences, age, past infections, and body weight—dictates this response and so the risk of severe disease. Focusing first on one aspect of this immunotype, weight, my research has made discoveries about vaccine failure in people with obesity. Poor maintenance of vaccine antibodies in people with obesity could be caused by dysregulated IL-6 signalling. I now propose to examine the impact of IL-6 signalling variability on vaccine responses in older people. Additionally, increasing the detail of our antibody maintenance studies through lymph node analysis and through mouse models of human variability. This research will then leverage the personalisation advantage of modified-mRNA therapeutics to develop specific strategies to overcome vaccine inequalities. We now create specific modified mRNA vaccines for genetic variants of pathogens or individual tumour mutations; similarly, my proposal will develop improved mRNA vaccine therapeutics by targeting deficiencies in individuals’ immunological characteristics. Given the growing proportion of the population that are older and living with obesity, this proposal addresses a vaccine-protection imbalance of increasing societal importance.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know